- Home
- RNAZ vs BTTR Comparison
RNAZ vs BTTR Comparison
Compare RNAZ & BTTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- BTTR
- Stock Information
- Founded
- RNAZ 2016
- BTTR 1986
- Country
- RNAZ United States
- BTTR United States
- Employees
- RNAZ N/A
- BTTR N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- BTTR Beverages (Production/Distribution)
- Sector
- RNAZ Health Care
- BTTR Consumer Staples
- Exchange
- RNAZ Nasdaq
- BTTR Nasdaq
- Market Cap
- RNAZ 4.9M
- BTTR 4.6M
- IPO Year
- RNAZ 2021
- BTTR N/A
- Fundamental
- Price
- RNAZ $3.35
- BTTR $2.13
- Analyst Decision
- RNAZ Strong Buy
- BTTR Strong Buy
- Analyst Count
- RNAZ 1
- BTTR 1
- Target Price
- RNAZ $20.00
- BTTR $10.00
- AVG Volume (30 Days)
- RNAZ 143.7K
- BTTR 27.2K
- Earning Date
- RNAZ 11-14-2024
- BTTR 11-12-2024
- Dividend Yield
- RNAZ N/A
- BTTR N/A
- EPS Growth
- RNAZ N/A
- BTTR N/A
- EPS
- RNAZ N/A
- BTTR N/A
- Revenue
- RNAZ N/A
- BTTR $33,519,000.00
- Revenue This Year
- RNAZ N/A
- BTTR $428.61
- Revenue Next Year
- RNAZ N/A
- BTTR $25.00
- P/E Ratio
- RNAZ N/A
- BTTR N/A
- Revenue Growth
- RNAZ N/A
- BTTR N/A
- 52 Week Low
- RNAZ $2.66
- BTTR $1.58
- 52 Week High
- RNAZ $66.33
- BTTR $14.80
- Technical
- Relative Strength Index (RSI)
- RNAZ 30.32
- BTTR 48.73
- Support Level
- RNAZ $2.90
- BTTR $1.98
- Resistance Level
- RNAZ $3.50
- BTTR $2.47
- Average True Range (ATR)
- RNAZ 0.42
- BTTR 0.17
- MACD
- RNAZ 0.31
- BTTR -0.03
- Stochastic Oscillator
- RNAZ 50.74
- BTTR 21.74
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About BTTR Better Choice Company Inc.
Better Choice Co Inc is a pet health and wellness portfolio company, offering consumers a wide variety of recognized premium pet products and hemp-derived CBD supplements. Its portfolio includes kibble and canned dog and cat food, freeze-dried raw dog food and treats, vegan dog food and treats, oral care products, supplements and grooming aids. Its core products sold under the Halo brand are sustainably sourced, derived from real whole meat and no rendered meat meal and include non-GMO fruits and vegetables. Its core products sold under the TruDog brand are made according to nutritional philosophy of fresh, meat-based nutrition and minimal processing.